foxo4-dri senolytic peptide human trial 2024 2025 Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions FOXO4-DRI: Human Trial Status, Cancer
FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Senolytic Interventions for Type 2 Diabetes: Current Evidence and Future Directions Senescent cells as a target for anti aging interventions: From senolytics to immune therapies PMC FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry
Pay in 4 interest-free payments of $5.35 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1




